Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
S086 vs olmesartan in primary hypertension
CTR20212325Phase 3Completed
- Sponsor
- Shenzhen Salubris Pharmaceuticals Co., Ltd.
- Start
- Sep 2021
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of S086 in essential hypertension, sponsored by Shenzhen Salubris Pharmaceuticals Co., Ltd.. Started Sep 2021; status: completed.
02
Drugs
S086
03
Conditions
essential hypertension
Beyond the preview
Go deeper on CTR20212325.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20212325.